Arthur M. Cohen & Associates LLC Lowers Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Arthur M. Cohen & Associates LLC lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,084 shares of the medical research company's stock after selling 1,244 shares during the period. Thermo Fisher Scientific comprises approximately 0.8% of Arthur M. Cohen & Associates LLC's investment portfolio, making the stock its 23rd biggest position. Arthur M. Cohen & Associates LLC's holdings in Thermo Fisher Scientific were worth $4,726,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of TMO. State Street Corp increased its holdings in Thermo Fisher Scientific by 0.8% in the 3rd quarter. State Street Corp now owns 16,318,961 shares of the medical research company's stock worth $10,100,655,000 after acquiring an additional 124,996 shares in the last quarter. FMR LLC raised its position in shares of Thermo Fisher Scientific by 19.7% during the 3rd quarter. FMR LLC now owns 7,877,459 shares of the medical research company's stock worth $4,872,761,000 after purchasing an additional 1,294,453 shares during the last quarter. Geode Capital Management LLC lifted its stake in Thermo Fisher Scientific by 1.7% in the 3rd quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock valued at $4,719,477,000 after buying an additional 127,564 shares in the last quarter. Franklin Resources Inc. increased its stake in Thermo Fisher Scientific by 5.7% during the 3rd quarter. Franklin Resources Inc. now owns 4,853,133 shares of the medical research company's stock worth $2,935,377,000 after buying an additional 262,062 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its position in shares of Thermo Fisher Scientific by 2.6% in the third quarter. Fisher Asset Management LLC now owns 2,636,558 shares of the medical research company's stock valued at $1,630,896,000 after acquiring an additional 65,586 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Down 0.4 %

TMO traded down $1.99 during mid-day trading on Friday, hitting $559.72. 2,134,669 shares of the stock were exchanged, compared to its average volume of 1,426,114. The company has a market cap of $214.09 billion, a PE ratio of 35.09, a PEG ratio of 3.59 and a beta of 0.76. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm's fifty day moving average is $529.96 and its two-hundred day moving average is $568.33. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating analysts' consensus estimates of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to analysts' expectations of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business's quarterly revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.69 earnings per share. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a stock repurchase program on Friday, November 15th that permits the company to buyback $4.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's board believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were paid a dividend of $0.39 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific's payout ratio is 9.78%.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the transaction, the executive vice president now owns 16,663 shares in the company, valued at approximately $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the sale, the chief executive officer now owns 121,192 shares in the company, valued at approximately $67,175,513.68. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,150 shares of company stock worth $25,954,465 in the last quarter. 0.34% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on TMO. Scotiabank initiated coverage on Thermo Fisher Scientific in a research note on Monday, December 23rd. They issued a "sector perform" rating and a $605.00 price objective for the company. Bernstein Bank raised their price target on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a "market perform" rating in a research note on Tuesday, October 22nd. Royal Bank of Canada dropped their price objective on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating for the company in a research note on Thursday, October 24th. StockNews.com upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, January 14th. Finally, Stephens initiated coverage on Thermo Fisher Scientific in a report on Tuesday, October 1st. They issued an "overweight" rating and a $680.00 price target for the company. Four investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $648.95.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.